Tempus Ai, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Tempus AI is registering the resale of up to 4,843,136 shares of Class A common stock by a selling stockholder, REALM IDx, Inc., following the acquisition of Ambry Genetics Corporation.
NASDAQ
Tempus AI, a healthcare technology company, is going public to further its mission of using AI to personalize diagnostics and treatment.
NASDAQ
Tempus AI, a healthcare technology company, has filed for an IPO to further its mission of transforming precision medicine through the application of artificial intelligence.
NASDAQ
S-1: Tempus AI Files for IPO, Aiming to Revolutionize Precision Medicine with AI-Powered Diagnostics
Tempus AI, a healthcare technology company, has filed for an initial public offering, seeking to expand its AI-driven precision medicine platform across various disease areas.